IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene BRCA1 Ensembl ENSG00000012048 Chromosome 17 Start 38449840 End 38530994
Description Breast cancer type 1 susceptibility protein (RING finger protein 53) [Source:UniProtKB/Swiss-Prot;Acc:P38398]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1100
     Entrez Gene : 672
     UCSC : uc002ict.2
     GeneCards : 1100
     RefSeq : NM_007294
     CCDS : CCDS11453.1
     Uniprot : P38398
     Interpro : P38398
     OMIM : 113705
     GeneTests : BRCA1
     CGAP : BRCA1
     PMID : 1676470

< Top >


Somatic Mutaions        (help)
Lung cancer Adenocarcinoma Squamous Cell Carcinoma
Unique Mutated Samples % Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
1 0.29 340 1 0.48 208 0 0.00 7
Sample datas
Sample Name Histology Subtype DNA Mutation Protein Mutation Mutation Description Zygosity Genomic Co-ordinates NCBI36 Pubmed
17226 AD c.3229G>T p.G1077W Substitution - Missense Heterozygous 17:38497845-3849784518948947

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
up 33/50(66%, 1.82)(Fold Change) qRT-PCRGender(P=0.016)//Histotype(P=0.012)//Grade(P=0.000) 19351853 Cancer Res. 2009 Apr 15;69(8):3390-6.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1993_s_at  0.74  4.82e-6  2.69e-5  1.40  2.00e-8  1.74e-7
 HG_U95  33724_at  0.35  1.97e-3  5.71e-3  0.77  1.20e-6  7.40e-6
 HG_U95  604_at  0.58  7.17e-4  2.34e-3  1.23  1.50e-6  9.00e-6
 HG_U133A  204531_s_at  0.97  1.83e-15  1.02e-14  -0.36  6.25e-3  6.83e-3
 HG_U133A  211851_x_at  1.05  3.04e-20  2.43e-19  -0.21  2.59e-1  2.69e-1
 HG_U133_Plus2  204531_s_at  0.78  6.90e-8  3.74e-7  1.17  4.60e-13  2.91e-12
 HG_U133_Plus2  211851_x_at  0.71  9.22e-7  4.19e-6  1.15  1.76e-12  1.04e-11
 Stanford  12890  1.23  7.73e-5  2.73e-3  1.84  3.32e-7  4.43e-5
 Agilent_HS_21.6K  16215  0.26  2.25e-3  1.46e-2  0.40  2.34e-6  3.23e-5

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204531_s_at  -0.28  5.90e-1  9.50e-1  0.18  4.04e-1  1.00e+0
 HG_U133A  211851_x_at  0.72  5.95e-2  7.22e-1  -0.01  9.51e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1993_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 33724_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 604_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204531_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211851_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204531_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211851_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 12890    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 16215    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
brca-1 gynecologic neoplasms Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. 11812938 Human
brca1 gynecomastia Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia. 15015615 Human
brca1 gynecomastia We demonstrated that BRCA1 proteins, like BRCA2, are widely expressed in the nuclei of epithelial cells surrounding the lumen of the ducts in infantile gynecomastia. 15015615 Human
brca1 gynecomastia The intensive nuclear staining of both proteins in the mammary tissues means that BRCA1 and BRCA2 proteins are largely expressed in infantile gynecomastia. 15015615 Human
brca-1 breast and ovarian cancer Thus prophylactic bilateral salpingo-oophorectomy can be regarded as an effective risk-reducing procedure that permits early diagnosis of ovarian cancer at the time of surgery and significantly reduces the risk of breast and ovarian cancer in women with g 14984481 Human
brca-1 ovarian cancer Thus prophylactic bilateral salpingo-oophorectomy can be regarded as an effective risk-reducing procedure that permits early diagnosis of ovarian cancer at the time of surgery and significantly reduces the risk of breast and ovarian cancer in women with g 14984481 Human
brca1 infiltrating carcinomas We have investigated the expression of BRCA1 protein in a series of 26 infiltrating carcinomas of male breast and correlated the results with a variety of clinicopathological parameters. 11859870 Human
brca1 second malignancy As such, their identification is essential to reduce the risk of disease in healthy carriers, as well as in carriers who have already developed the disease because they are at increased risk for a second malignancy; moreover, noncarriers of BRCA1 and BRCA 11920643 Human
brca1 invasive lobular carcinoma Here, we show the presence of a post-transcriptional mechanism by examining promoter hypermethylation, mRNA expression levels and immunoreactivity of BRCA1 in sporadic human breast cancers METHODS: Paired samples of 20 invasive ductal carcinomas and one i 11956301 Human
brca1 breast and ovarian cancer Mutations in BRCA1 and BRCA2 confer a high risk of breast and ovarian cancer, but account for only a small fraction of breast cancer susceptibility. 11967536 Human
brca1 male breast cancer However, this variant is present in 5.1% of individuals with breast cancer from 718 families that do not carry mutations in BRCA1 or BRCA2 (P = 0.00000003), including 13.5% of individuals from families with male breast cancer (P = 0.00015). 11967536 Human
brca1 ism We have analyzed 30 patients for inherited susceptibility mutations (ISM) within exon 11 of the BRCA1 gene as part of an ongoing genetic epidemiological study of high-risk breast cancer (HRBC). 12007222 Human
brca1 gynecologic cancer BACKGROUND: Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutations are limited. 12023993 Human
brca1 epithelial cancer CONCLUSIONS: Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial cancer and breast cancer in women with BRCA1 or BRCA2 mutations. 12023993 Human
brca1 breast and ovarian cancers Germ-line mutations in BRCA1 predispose individuals to breast and ovarian cancers. 11916966 Human
brca1 xeroderma pigmentosum We find that the Xeroderma Pigmentosum Complementation group E (XPE) mutated Damaged-DNA binding protein p48 (DDB2) is upregulated by BRCA1 in a p53-dependent manner following UVC, Adriamycin, or Cisplatin exposure. 12170778 Human
brca1 ewings sarcoma Because BARD1 associates via its NH2-terminal RING domain with the breast cancer susceptibility gene BRCA1 that provides a platform for interactions with proteins involved in DNA repair and checkpoint control, our results provide a link between the Ewing& 12183411 Human
brca1 rectal cancer Mutation analysis showed the presence of a nonsense mutation within BRCA1 exon 12 in two individuals, mother and daughter, affected by breast and peritoneal cancer, respectively, as well as in the son, who had rectal cancer at the early age of 27 years. 12217765 Human
brca1 cancer predisposition syndromes Although breast cancer is a component tumor of several familial cancer predisposition syndromes, mutations in BRCA1 and BRCA2 are the most commonly identified germline changes. 12382194 Human
brca1 breast and ovarian cancer The BRCA1 gene was cloned in 1994 as one of the genes that conferred genetic predisposition to early-onset breast and ovarian cancer. 12383682 Human
brca1 secondary cancer We examine the mechanisms that underlie inactivation of BRCA1 and assess how they affect management of patients, in terms of both primary and secondary cancer prevention strategies. 12383682 Human
brca1 ovarian malignancies We investigated the BRCA1 gene copy number in unselected ovarian malignancies. 15010292 Human
brca1 lymph-node metastasis In addition, loss of BRCA1 expression was also related to poor tumor differentiation and lymph node metastasis. 12552965 Human
brca1 hereditary breast cancer BACKGROUND: Many cases of hereditary breast cancer are due to mutations in either the BRCA1 or the BRCA2 gene. 11207349 Human
brca1 invasive cancers Among the 515 women with invasive cancers, we identified 60 mutations, 39 in BRCA1 and 21 in BRCA2. 11179017 Human
brca1 nevoid-basal-cell-carcinoma syndrome Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. 11231326 Human
brca1 invasive carcinomas RESULTS: Twenty-seven individuals with invasive carcinomas were found to have mutations (14 with 185delAG and one with 5382insC in BRCA1 and 12 with 6174delT in BRCA2). 11373105 Human
brca1 invasive carcinomas For the invasive carcinomas, there was a survival advantage for BRCA1 and BRCA2 patients compared to patients without mutations, though the differences were not statistically significant. 11373105 Human
brca1 endocrine tumors TSG genetic lesions, such as BRCA1 in breast cancer and p53 in Li-Fraumeni Syndrome, have been identified in both sporadic and heritable human endocrine tumors. 11414476 Human
brca1 breast tumors CONCLUSIONS: These data suggest that age at diagnosis, possibly related to menopausal status, may be an important factor in the expression of specific proteins in breast tumors of BRCA1 mutation carriers. 11448907 Human
brca1 primary malignancies Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. 11451557 Human
brca1 primary malignancies A case of three primary malignancies related to the BRCA1 185delAG mutation successively occurring in a carrier of this mutation, is described. 11451557 Human
brca1 adnexal carcinoma STUDY DESIGN: Ovarian surfaces were scraped to retrieve OSE cells from 56 women at hereditary high risk for female adnexal carcinoma, of whom 33 are BRCA1 and four are BRCA2 mutation carriers (Predisposed OSE, POSE) and from 26 women without such risk (No 14984947 Human
brca-1 small-cell carcinoma Laser capture microdissection followed by loss of heterozygosity (LOH) analysis revealed identical molecular alterations at multiple chromosomal regions, including BRCA-1, BRCA-2, p53, and retinoblastoma gene loci, in 1 case of small-cell carcinoma and it 11486176 Human
brca1 oral carcinomas Furthermore, 10.0% of oral carcinomas exhibited LOH for NER factors without LOH for tumor suppressor genes such as p53, FHIT, APC, BRCA1, BRCA2 and DCC. 11496330 Human
brca1 breast cancer We have identified the physical interaction between the Breast Cancer susceptibility gene product BRCA1 and the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and DNA mismatch repair (MMR) gene product hMSH2, both in vitro and in vivo. 11498787 Human
brca1 atypical ductal hyperplasia In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 11577167 Human
brca1 lobular carcinoma in situ In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 11577167 Human
brca1 serous adenocarcinoma In consideration of clinicopathological features, there was a significantly higher proportion of tumors with serous adenocarcinoma and of cases of advanced stages in the BRCA1 or BRCA2 cases than in those of the controls. 11595708 Human
brca1 occult carcinoma The remaining five patients, all BRCA1 mutation positive, showed occult carcinoma of the ovaries and/or in situ or invasive carcinoma of a fallopian tube. 11688463 Human
brca1 invasive carcinoma The remaining five patients, all BRCA1 mutation positive, showed occult carcinoma of the ovaries and/or in situ or invasive carcinoma of a fallopian tube. 11688463 Human
brcai lung carcinomas Furthermore, 13.8% of ovarian, 8.3% of colon and 22% of lung carcinomas exhibited LOH for NER factors without LOH for tumor suppressor genes such as p53, FHIT, APC, BRCAI, BRCA2 and DCC. 11689286 Human
brca1 chromosomal breakage syndromes Chromosomal breakage syndromes and the BRCA1 genome surveillance complex. 11733219 Human
brca1 primary peritoneal serous papillary carcinoma (ppspc) The aim of the study was to examine the prevalence of primary peritoneal serous papillary carcinoma (PPSPC) as compared with ovarian serous papillary cancer (OSPC), and to study the clinicopathologic features and the frequency of germline BRCA1 and BRCA2 11737473 Human
brca1 malignant melanoma of the skin Increased risks were found for cancers that are part of the BRCA1 and BRCA2 tumour spectrum: oropharyngeal cancer, malignant melanoma of the skin (BRCA2) and colon cancer (BRCA1). 11745474 Human
brca1 oropharyngeal cancer Increased risks were found for cancers that are part of the BRCA1 and BRCA2 tumour spectrum: oropharyngeal cancer, malignant melanoma of the skin (BRCA2) and colon cancer (BRCA1). 11745474 Human
brca1 sporadic ovarian cancer Understanding the risk factors for sporadic ovarian cancer and the recently recognized inherited susceptibility for ovarian cancer associated with BRCA1 and BRCA2 gene mutations may allow physicians to identify women who might benefit from prophylactic oo 11766142 Human
brca1 ovarian cancer Understanding the risk factors for sporadic ovarian cancer and the recently recognized inherited susceptibility for ovarian cancer associated with BRCA1 and BRCA2 gene mutations may allow physicians to identify women who might benefit from prophylactic oo 11766142 Human
brca1 uterine papillary serous carcinoma No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report. 11766733 Human
brca1 atypical hyperplasia However, raloxifene is the more cost-effective alternative for women at average coronary risk with one or more major breast cancer risk factors (first-degree relative, prior breast biopsy, atypical hyperplasia or BRCA1/2 mutation). 11755544 Human
brca-1 invasive carcinoma The second group included women who underwent prophylactic subcutaneous mastectomy after genetic counseling for either carrying the BRCA-1 gene or belonging to a pedigree with familial breast cancer (FAM), and the third group included women who underwent 11906437 Human
brca-1 invasive cancer The data suggest that the breast tissue of women with invasive cancer, as well as those from a background of familial breast cancer, have an architectural pattern different from the control or normal tissues and that the BRCA-1 or related genes may have a 11906437 Human
brca1 rous sarcoma Finally, full-length BRCA1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which was further stimulated by p300. 10655477 Human
brca1 secondary cancer PARTICIPANTS: Hypothetical breast cancer patients with BRCA1 or BRCA2 mutations facing decisions about secondary cancer prevention strategies. 10665701 Human
brca1 cancer Our results support the usefulness of induced micronucleus frequencies as a biomarker for cancer predisposition and suggest its application as a screening test for carriers of a BRCA1 mutation in breast cancer families. 10667592 Human
brca1 pancreatic adenocarcinoma Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. 10667595 Human
brca1 pancreatic cancer The objectives of this study were to estimate the proportion of unselected pancreatic cancer patients belonging to hereditary cancer syndrome families and to determine the frequency ofp16, BRCA1, BRCA2, hMSH2, and hMLH1 germ-line mutations in patients wit 10667595 Human
brca1 chondrosarcoma This trait is most probably not associated with mutations in the two major hereditary breast cancer genes since no cases of enchondroma or chondrosarcoma were found in Dutch BRCA1 and BRCA2 families. 14661035 Human
brca1 enchondroma This trait is most probably not associated with mutations in the two major hereditary breast cancer genes since no cases of enchondroma or chondrosarcoma were found in Dutch BRCA1 and BRCA2 families. 14661035 Human
brca1 an adenocarcinoma A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone. 15138940 Human
brca1 ovarian epithelial tumors Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. 10685639 Human
brca1 clear-cell carcinoma Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. 10749023 Human
brca1 clear-cell carcinoma We report the case history of a patient with a family history of breast and ovarian cancer who was subsequently found to be a carrier of the BRCA1 gene, in whom a tiny focus of clear cell carcinoma was found at the fimbrial end of one fallopian tube when 10749023 Human
brca1 metaplasia Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation. 10770566 Human
brca1 gynecological cancers Mutations in the p53, BRCA1, DCC, and PTEN genes have been reported in gynecological cancers such as ovarian, cervical, and endometrial cancer. 10818392 Human
brca1 an adenocarcinoma BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary. 10882335 Human
brca1 metastatic carcinoma We report here on how the suggestion by family history of a BRCA1 mutation guided the diagnostic and therapeutic approach in a patient with metastatic carcinoma of unknown primary. 10882335 Human
brca1 adenocarcinoma of unknown primary CONCLUSIONS: This case illustrates an unusual presentation of adenocarcinoma of unknown primary in a patient with a germline BRCA1 mutation, the use of a suspected germline mutation to guide the work-up and treatment, and finally the value of positron emi 10882335 Human
brca1 familial breast cancer BRCA1 encodes a familial breast cancer suppressor that has a critical role in cellular responses to DNA damage. 10910365 Human
brca1 cysts METHODS: Ovarian tissues from 18 BRCA1 heterozygotes and from 20 age-matched controls were examined in a blinded fashion for histologic evidence of surface epithelial pseudostratification, epithelial inclusion cysts, deep cortical invaginations of surface 10918170 Human
brca1 carcinomas Decreased expression of BRCA1 was found in 16% of benign tumours, 38% of borderline tumours, and 72% of carcinomas. 14743504 Human
brca1 serous carcinomas The frequency of BRCA1 methylation and LOH was higher in serous carcinomas than in other types. 14743504 Human
brca1 serous carcinomas In one of the three serous carcinomas that showed heterogeneous expression of BRCA1, BRCA1-positive borderline-like tumour cells were LOH-positive and methylation-negative, whereas adjacent BRCA1-negative carcinoma cells were LOH-positive and methylation- 14743504 Human
brca-1 medullary carcinomas This feature is also found in BRCA-1 associated tumors that shared several histologic characteristics with medullary carcinomas of the breast. 14614327 Human
brca1 medullary carcinoma of the breast Medullary carcinoma of the breast and BRCA1 mutation. 10931243 Human
brca1 female breast cancer Mutations in BRCA1 (ref. 1) confer an increased risk of female breast cancer. 10932184 Human
brca1 peritoneal carcinomatosis To gain an understanding of the molecular mechanisms of ovarian cancer, we analyzed 16 ovarian tumors from Jewish Israeli patients by comparative genomic hybridization: 12 invasive epithelial tumors (including three BRCA1 and one BRCA2 mutation carriers), 10958937 Human
brca1 bone sarcomas The increased risk of ovarian cancer is consistent with germline mutations in the BRCA1 and BRCA2 genes, while the risk of soft tissue and bone sarcomas may reflect the association of these tumours with Li-Fraumeni syndrome. 10962444 Human
brca1 recurrent tumors BRCA1 methylation status of the primary tumor was conserved in six recurrent tumors after interim chemotherapy. 11034065 Human
brca1 large-cell carcinomas Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. 14647419 Human
brca1 adenoma of the colon A germline 3938insG mutation in BRCA1 was found in 5 breast-cancer patients, 1 with ductal carcinoma in situ, ovarian cancer and an adenoma of the colon, and in 4/5 colorectal-cancer patients investigated. 11072248 Human
brca1 adenoma Loss of the wild-type BRCA1 allele was observed in 3/3 breast tissues (2 breast carcinomas and 1 ductal carcinoma in situ) but in 0/6 colorectal tissues (5 carcinomas and 1 adenoma), suggesting that BRCA1 loss is not critical for colorectal tumorigenesis. 11072248 Human
brca1 hyperplasias Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1Delta11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary g 11077440 Human
brca1 hyperplasias Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1Delta11, in tumors higher than those in the hyperplasias. 11077440 Human
brca1 ovarian dysgerminoma Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. 11109172 Human
brca1 dysgerminoma The development of the proband's dysgerminoma may be unrelated to her germline BRCA1 mutation. 11109172 Human
brca1 medullary-thyroid carcinoma At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
brca1 cancer We examined the transcriptional activity of two known sequence alterations in BRCA1, one that results in a carboxy-terminal truncation of BRCA1 and is clearly pathogenic, and the other a missense mutation that is suspected of predisposing to cancer. 11175350 Human
brca1 ovarian adenocarcinoma Introduction of BRCA1 antisense retroviral constructs into BG-1 estrogen-dependent ovarian adenocarcinoma cells resulted in reduced BRCA1 expression. 11056686 Human
brca1 ovarian adenocarcinoma These data suggest that reduction of BRCA1 protein in BG-1 ovarian adenocarcinoma cells may have an effect on cell survival during estrogen deprivation both in vitro and in vivo. 11056686 Human
brca1 breast and ovarian cancer BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. 10597248 Human
brca1 melanoma N-acetyl-leu-leu-norleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BR 10597248 Human
brca1 serous adenocarcinoma The high frequencies of breast ovarian cancer syndrome, serous adenocarcinoma, high histological grades, advanced FIGO stages, and breast cancer as double cancer were found to be characteristic of ovarian cancer with germline mutations in BRCA1. 10634513 Human
brca1 gynecologic cancer To characterize the involvement of the BRCA1 and TP53 tumor suppressor genes and of the KRAS2 protooncogene in gynecologic cancer, mutation analysis of these genes was conducted in pelvic tumors of 85 patients that included 49 epithelial ovarian carcinoma 10686936 Human
brca1 colorectal cancer BACKGROUND: Chromosome regions 17q21 (BRCA1) and 10q23 (PTEN) have been found deleted in colorectal cancer. 14527905 Human
brca-1 colonic adenocarcinomas Deoxycholate, an endogenous tumor promoter and DNA damaging agent, modulates BRCA-1 expression in apoptosis-sensitive epithelial cells: loss of BRCA-1 expression in colonic adenocarcinomas. 12925308 Human
brca-1 colon adenocarcinomas We show that BRCA-1 is substantially lower in colon adenocarcinomas from five patients compared with associated non-neoplastic colon tissue from the same patients, suggesting that the loss of BRCA-1 expression contributes to the malignant phenotype. 12925308 Human
brca1 ductal carcinomas Immunohistochemical staining of human breast specimens also revealed BRCA1 nuclear foci in benign breast, invasive lobular cancers and low-grade ductal carcinomas. 9988281 Human
brca1 ductal carcinomas Conversely, BRCA1 expression was reduced or undetectable in the majority of high-grade, ductal carcinomas, suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers. 9988281 Human
brca1 gynecomastia To determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary, the country with the highest male breast cancer mortality rates in continental Europe, a series of 18 male breast cancer patients and three pa 10070953 Human
brca1 esophageal cancer Since the BRCA1 gene lies at 17q21.1 and the TOC locus, associated with esophageal cancer, lies at 17q25.1, either gene could be the target of those losses. 10092133 Human
brca1 lymph-node metastases LOH in the BRCA1 region was found in 47% of tumors, correlating significantly with estrogen receptor content (p = 0.025), progesterone receptors (p = 0.004), higher grade (p = 0.0008), peritumoral vessel invasion (p = 0.001), and lymph node metastases (p 10206068 Human
brca1 peritumoral vessel invasion LOH in the BRCA1 region was found in 47% of tumors, correlating significantly with estrogen receptor content (p = 0.025), progesterone receptors (p = 0.004), higher grade (p = 0.0008), peritumoral vessel invasion (p = 0.001), and lymph node metastases (p 10206068 Human
brca1 lymph-node metastases Concomitant losses in the BRCA1 and BRCA2 regions were found in 32% of cases, correlating significantly with lymph node metastases (p = 0.0002), estrogen receptor content (p = 0.003), progesterone receptors (p = 0.001), histologic grade (p = 0.01), and pe 10206068 Human
brca1 peritumoral vessel invasion Concomitant losses in the BRCA1 and BRCA2 regions were found in 32% of cases, correlating significantly with lymph node metastases (p = 0.0002), estrogen receptor content (p = 0.003), progesterone receptors (p = 0.001), histologic grade (p = 0.01), and pe 10206068 Human
brca1 carcinoma in situ Breast cancers occurring in BRCA1 mutation carriers had significantly higher levels of p53 expression, including the preinvasive (carcinoma in situ) stage of disease, compared with cancers occurring in BRCA2 mutation carriers or women with no detectable g 10213514 Human
brca1 occult carcinoma At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. 15083174 Human
brca1 breast cancer Mutations of the breast cancer susceptibility gene BRCA1 confer increased risk for breast, ovarian, and prostatic cancers, but it is not clear why the mutations are associated with these particular tumor types. 10334989 Human
brca1 prostatic cancers Mutations of the breast cancer susceptibility gene BRCA1 confer increased risk for breast, ovarian, and prostatic cancers, but it is not clear why the mutations are associated with these particular tumor types. 10334989 Human
brca1 meningioma Inclusion criteria were 1. family history of breast cancer; 2. absence of germline BRCA1 and p53 mutation; and 3. at least one case of brain tumour (glioblastoma, meningioma, or medulloblastoma) in either the index case or one of their first or second deg 10371336 Human
brca1 glioblastoma Inclusion criteria were 1. family history of breast cancer; 2. absence of germline BRCA1 and p53 mutation; and 3. at least one case of brain tumour (glioblastoma, meningioma, or medulloblastoma) in either the index case or one of their first or second deg 10371336 Human
brca1 adnexal carcinoma Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma. 12819403 Human
brca1 gynecological cancer In a survey of hereditary breast cancer genes in gynecological cancer, we analyzed the entire coding sequence of BRCA1 and BRCA2 in 51 endometrial tumors, of which 12 were RER+. 10451700 Human
brca1 endometrial tumors In a survey of hereditary breast cancer genes in gynecological cancer, we analyzed the entire coding sequence of BRCA1 and BRCA2 in 51 endometrial tumors, of which 12 were RER+. 10451700 Human
brca1 hereditary breast cancer In a survey of hereditary breast cancer genes in gynecological cancer, we analyzed the entire coding sequence of BRCA1 and BRCA2 in 51 endometrial tumors, of which 12 were RER+. 10451700 Human
brca1 tumors Two tumors exhibited frameshift mutations at polyA tracts in BRCA1 and BRCA2 exon 11, both predicted to result in premature translation termination. 10451700 Human
brca1 endometrial carcinomas Moreover, our results suggest that somatic mutations in BRCA2(and to some extent BRCA1) may confer a growth advantage in RER+ endometrial carcinomas. 10451700 Human
brca1 recurrent breast cancer BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. 10506595 Human
brca1 papillary carcinomas CONCLUSIONS: We present a breast-ovarian cancer family including two sisters with advanced serous papillary carcinomas of endometrial and ovarian origins, carrying the same BRCA1 mutation (5382insC). 10525392 Human
brca1 papillary serous carcinomas We compared molecular alterations in histologically homologous ovarian and uterine carcinomas, including the prevalence of allelic loss of markers on 17q (within and distal to the familial breast-ovarian cancer gene BRCA1), mutations of codon 12 of Ki-ras 9500773 Human
brca1 secondary cancers Since some of the DNA-damaging mutagens tested here are used as cytostatics in breast cancer chemotherapy, it might be that women with a BRCA1 mutation are at higher risk for the induction of mutations and secondary cancers by standard therapies. 14644329 Human
brca1 medullary breast carcinoma Mutations at BRCA1: the medullary breast carcinoma revisited. 9563465 Human
brca1 borderline ovarian tumors Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. 9665148 Human
brcai sporadic breast cancer CONCLUSIONS: Despite their younger age at presentation, breast cancer patients harboring BRCAI or BRCA2 mutations present at a similar stage, display a normal acute reaction to radiotherapy and have a similar prognosis when compared with sporadic breast c 9683359 Human
brca1 papilloma There was much less BRCA1 antibody staining in normal tissues; however, 2 intraductal tumors and a papilloma, found in proximity to the carcinomas showed considerable nucleolar immunoreactivity. 9683786 Human
brca1 papillary serous ovarian carcinoma OBJECTIVE: To compare BRCA1 mutations in papillary serous carcinoma of the peritoneum and papillary serous ovarian carcinoma. 9764635 Human
brca1 invasive breast cancer CONCLUSION: BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated b 14680495 Human
brca1 low-grade tumors All low grade tumors and tumors with low mitotic rates belonged to the group without BRCA1 or BRCA2 mutations. 9840533 Human
brca1 medullary carcinomas We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular ca 9872332 Human
brca1 invasive lobular carcinomas We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular ca 9872332 Human
brca1 squamous-cell carcinoma In order to investigate the implication of these novel TSGs in the development of laryngeal neoplasia we performed a loss of heterozygosity (LOH) analysis using a bank of 15 polymorphic microsatellite markers (4 at 8p21, 7 at 9p21 arm and 4 at 17q arm sur 9930365 Human
brca1 female breast cancer Germline mutations of a second cancer susceptibility gene BRCA1 (ref. 5), are associated with a strong predisposition to ovarian cancer as well as female breast cancer. 8988179 Human
brca1 second cancer Germline mutations of a second cancer susceptibility gene BRCA1 (ref. 5), are associated with a strong predisposition to ovarian cancer as well as female breast cancer. 8988179 Human
brca1 ovarian cancer Germline mutations of a second cancer susceptibility gene BRCA1 (ref. 5), are associated with a strong predisposition to ovarian cancer as well as female breast cancer. 8988179 Human
brca1 ovarian cancer Recent studies have suggested that the phenotype in BRCA1 families with respect to the ratio of breast to ovarian cancer varies with the location of the BRCA1 mutation. 8988179 Human
brca1 breast cancer This yeast-based stop codon assay accurately detects heterozygous truncating mutations in the BRCA1 gene in patients with early onset of breast cancer and in the APC gene in patients with familial adenomatous polyposis. 9122215 Human
brca1 breast cancer BACKGROUND: Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. 9145676 Human
brca1 colon cancer There were no significant differences in the risk of breast cancer between carriers of BRCA1 mutations and carriers of BRCA2 mutations, and the incidence of colon cancer among the relatives of carriers was not elevated. 9145676 Human
brca1 prostate cancer CONCLUSIONS: Over 2 percent of Ashkenazi Jews carry mutations in BRCA1 or BRCA2 that confer increased risks of breast, ovarian, and prostate cancer. 9145676 Human
brca1 bilateral breast cancer No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation, or between the position of the mutation in the BRCA1 gene and the presence of ovarian cancer in a f 9145677 Human
brca1 stage-ii breast cancers Prior to BRCA1 analysis, 79 breast and 19 ovarian tumours from 57 breast and breast-ovarian cancer families, and 170 tumours from a comparison group of stage II breast cancers were studied with regard to histopathological features; immunohistochemistry [c 9155518 Human
brca1 invasive ductal carcinoma The occurrence of invasive lobular carcinoma and invasive ductal carcinoma was not significantly different between carriers of BRCA1 or BRCA2 mutations and controls. 9167459 Human
brca1 invasive lobular carcinoma The occurrence of invasive lobular carcinoma and invasive ductal carcinoma was not significantly different between carriers of BRCA1 or BRCA2 mutations and controls. 9167459 Human
brca-1 papillomas DNA samples from microdissected PBD lesions, including papillomas (25 lesions), from 8 women were analyzed by polymerase chain reaction for loss of heterozygosity and microsatellite instability at 10 loci including INT-2 oncogene locus, D17S796 (the p53 g 9176386 Human
brca1 meningiomas Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas. 9290954 Human
brca1 meningiomas Evaluation of 60 sporadic meningiomas with a panel of eight microsatellite and two restriction fragment length polymorphism markers at the locations of BRCA1 and BRCA2 demonstrated no loss of heterozygosity. 9290954 Human
brca1 meningiomas These results suggest that alterations of the BRCA1 and BRCA2 genes are not common pathogenetic events in the development of sporadic meningiomas. 9290954 Human
brca1 lymphoblastic lymphomas Significantly, DNA-PKcs null mice demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that Prkdc functions in mice as a T-cell tumour suppressor and, by virtue of its association with DNA repair and recombination, belong 9398856 Mouse
brca1 lung cancer Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts. 8589721 Human
brca1 borderline ovarian tumors These results suggest that inactivation of the BRCA1 gene may not be responsible for the development of borderline ovarian tumors and that another tumor suppressor gene, located centromeric to the BRCA1 gene, may play a role in sporadic ovarian cancer dev 8632895 Human
brca1 lung cancer Other tumor types found in BRCA1 mutation/haplotype carriers included prostatic, pancreas, skin, and lung cancer, a malignant melanoma, an oligodendroglioma, and a carcinosarcoma. 8644702 Human
brca1 oligodendroglioma Other tumor types found in BRCA1 mutation/haplotype carriers included prostatic, pancreas, skin, and lung cancer, a malignant melanoma, an oligodendroglioma, and a carcinosarcoma. 8644702 Human
brca1 carcinosarcoma Other tumor types found in BRCA1 mutation/haplotype carriers included prostatic, pancreas, skin, and lung cancer, a malignant melanoma, an oligodendroglioma, and a carcinosarcoma. 8644702 Human
brca1 invasive lobular carcinoma For BRCA1 (D17S855, THRA1, D17S579) losses could be detected in invasive ductal carcinoma (IDC; n = 108) in 32-38%, invasive lobular carcinoma (ILC; n = 19) in 21-42% depending on the marker applied, but not in benign breast tumours (n = 15). 8630282 Human
brca1 invasive carcinomas Invasive carcinomas from the deleterious mutation carriers in the unilateral cohort were of higher grade compared with the control group (P = 0.003) and patients without a mutation (P < 0.0001) but were of similar grade compared with carriers of unclassif 12491499 Human
brca1 ovarian cystadenoma Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. 15131356 Human
brca1 cystadenoma The study aimed to determine whether hereditary ovarian cancers that are not caused by BRCA1/BRCA2 constitutional mutations are associated with a predisposition to cystadenoma. 15131356 Human
brca1 ovarian cystadenoma Part one concerned the incidence of ovarian cystadenoma in females from families with hereditary ovarian cancer unassociated with BRCA1 mutations. 15131356 Human
brca1 cystadenoma We concluded that cystadenoma is likely to be a characteristic feature of the subgroup of families with hereditary ovarian cancers unassociated with BRCA1/BRCA2 constitutional mutations. 15131356 Human
brca1 stage-ii breast cancer PATIENTS AND METHODS: Patients included 491 women with stage I or stage II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. 15197194 Human
brca1 breast cancer BRCA1 and BRCA2 are the two major identified causes of inherited breast cancer, with mutations in either gene conferring up to 80-90% lifetime risk of breast cancer in carrier females. 8841191 Human
brca1 inherited breast cancer BRCA1 and BRCA2 are the two major identified causes of inherited breast cancer, with mutations in either gene conferring up to 80-90% lifetime risk of breast cancer in carrier females. 8841191 Human
brca1 breast-ovarian cancer Mutations in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast/ovarian cancer, whereas mutations in BRCA2 account for a comparable percentage of inherited breast cancer cases. 8841191 Human
brca1 familial breast cancer Mutations in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast/ovarian cancer, whereas mutations in BRCA2 account for a comparable percentage of inherited breast cancer cases. 8841191 Human
brca1 inherited breast cancer Mutations in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast/ovarian cancer, whereas mutations in BRCA2 account for a comparable percentage of inherited breast cancer cases. 8841191 Human
brca1 breast cancer The breast cancer susceptibility gene BRCA1 encodes an 1863-amino acid protein that acts as a tumor suppressor. 8910495 Human
brca 1 leukaemia CONCLUSIONS: It is postulated that alkylating agents with or without p53 gene inactivation may predispose to leukaemia, whereas ovarian tumors following breast cancer could be related to BRCA 1 gene inactivation. 8944062 Human
brca1 pancreatic adenocarcinoma A family history of pancreatic adenocarcinoma is not common in patients with this disease, but recent research has shown that pancreatic adenocarcinoma can be a feature of cancer susceptibility syndromes associated with germline mutations in p16, BRCA1, B 8950667 Human
brca1 breast carcinoma Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. 12548593 Human
brca1 breast and ovarian cancer Identification and isolation of BRCA1 will likely provide the basis for increased understanding of the pathogenesis of breast and ovarian cancer, the development of targeted diagnostic and therapeutic approaches, and a means of screening women at risk of 7749139 Human
brca1 thymic lymphoma Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. 12555066 Mouse
brca1 neurofibromatosis Nonsense or frameshift mutations, which result in a truncated gene product, are prevalent in a variety of disease-related genes, including APC (implicated in colorectal cancer), BRCA1 and BRCA2 (breast and ovarian cancer), PKD1 (polycystic kidney disease) 12524552 Human
brca1 carcinoma in situ BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive cancer. 7795653 Human
brca1 invasive cancer BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive cancer. 7795653 Human
brca1 hereditary ovarian carcinomas These data are consistent with the hypothesis that BRCA1 mutations are involved in the etiology of hereditary ovarian carcinomas but occur rarely in sporadic tumors, and that the frequent allelic loss on chromosome 17q in this cancer type reflects the inv 7606717 Human
brca1 breast and ovarian cancer Since BRCA1, the first major gene responsible for inherited breast cancer, was cloned, more than 50 unique mutations have been detected in the germline of individuals with breast and ovarian cancer. 7550349 Human
brca1 inherited breast cancer Since BRCA1, the first major gene responsible for inherited breast cancer, was cloned, more than 50 unique mutations have been detected in the germline of individuals with breast and ovarian cancer. 7550349 Human
brca1 breast cancer In high-risk pedigrees, female carriers of BRCA1 mutations have an 80-90% lifetime risk of breast cancer, and a 40-50% risk of ovarian cancer. 7550349 Human
brca1 ovarian cancer In high-risk pedigrees, female carriers of BRCA1 mutations have an 80-90% lifetime risk of breast cancer, and a 40-50% risk of ovarian cancer. 7550349 Human
brca1 renal cancer Examples include the RB1 gene for retinoblastoma; the WT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tu 8741802 Human
brca1 wilms tumor Examples include the RB1 gene for retinoblastoma; the WT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tu 8741802 Human
brca1 common cancers Examples include the RB1 gene for retinoblastoma; the WT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tu 8741802 Human
brca1 second cancers In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 7907678 Human
brca1 squamous-cell carcinomas Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus. 7907942 Human
brca1 ductal breast carcinomas High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. 8169978 Human
brca1 male breast cancer Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. 8075631 Human
brca1 breast and ovarian cancer We have examined 22 families with at least one case of male breast cancer for linkage to the hereditary breast and ovarian cancer locus, BRCA1, on chromosome 17q. 8075631 Human
brca1 male breast cancer We have examined 22 families with at least one case of male breast cancer for linkage to the hereditary breast and ovarian cancer locus, BRCA1, on chromosome 17q. 8075631 Human
brca1 bladder cancer We have studied chromosomal deletions in the BRCA1 region in seven breast tumors, three ovarian tumors, one bladder cancer, and one colon cancer from patients in six families with breast-ovarian cancer, in order to test the hypothesis of the tumor suppres 8076936 Human
brca1 ovarian carcinomas BRCA1 mutations in primary breast and ovarian carcinomas. 7939630 Human
brca1 early-onset breast cancer Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. 7939630 Human
brca1 breast and ovarian cancers These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele. 7939630 Human
brca1 axillary lymph node metastasis A human tumor xenograft (L56Br-X1) was established from a breast cancer axillary lymph node metastasis of a 53-year-old woman with a BRCA1 germ-line nonsense mutation (1806C>T; Q563X), and a cell line (L56Br-C1) was subsequently derived from the xenograft 12649339 Human
brca1 acute leukemia The characterization of 6 anti-BRCA1 antibodies revealed a BRCA1 200-kDa protein detected in breast cell lines (MDA-MB 231, HBL 100, T-47D and MCF7) or in an acute leukemia (MOLT 4), known to overexpress BRCA1. 12680164 Human
brca1 metaplastic carcinoma One patient with a chondroid metaplastic carcinoma was found to be a carrier of a BRCA1 mutation similar to the one responsible for sickle cell disease, possibly altering the spatial structure of the gene product. 12680165 Human
brca1 metastatic disease The rate of prophylactic bilateral and contralateral mastectomy and prophylactic oophorectomy was analyzed in the women who carried a BRCA1/BRCA2 mutation and who had no metastatic disease at the time of the genetic test disclosure. 12721241 Human
brca-1 medullary breast carcinoma Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. 12752644 Human
brca1 ductal carcinomas A progressive loss of BRCA1 expression correlated well with higher histological grade (p = 0.002) and an excess of medullary/atypical medullary/grade 3 ductal carcinomas (p = 0.0001). 12754741 Human
brca1 blast crisis BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. 12576338 Human
brca1 primary testicular lymphoma We studied the methylation status of E-cadherin, CDKN2B, CDKN2A, BRCA1, RB1, VHL, RASSF1A, RARB, and GSTP1 by use of TGCT tissues and testicular malignant lymphoma tissues (25 primary TGCT tissues and three primary testicular lymphoma tissues). 12874790 Human
brca1 malignant lymphoma We studied the methylation status of E-cadherin, CDKN2B, CDKN2A, BRCA1, RB1, VHL, RASSF1A, RARB, and GSTP1 by use of TGCT tissues and testicular malignant lymphoma tissues (25 primary TGCT tissues and three primary testicular lymphoma tissues). 12874790 Human
brca1 testicular lymphoma In contrast, all three (100%) of the testicular lymphoma tissues demonstrated hypermethylation of E-cadherin, RASSF1A, and RARB, but not CDKN2B, CDKN2A, BRCA1, RB1, VHL, and GSTP1. 12874790 Human
brca1 leukoplakia BRCA1 expression in leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 leukoplakia BACKGROUND AND OBJECTIVES: Expression of BRCA1 was examined in patients with leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 leukoplakia Cytoplasmic staining of BRCA1 was observed in both leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 leukoplakia RESULTS: In leukoplakia, 61% and 39% of the patients expressed BRCA1 expression with a staining intensity of 1+ and 2+, respectively. 12884236 Human
brca1 squamous-cell carcinoma Moreover, BRCA1 expression with a staining intensity of 2+ was significantly higher in patients with dysplasia (50%) than in those with hyperplasia (33%), followed by patients with squamous cell carcinoma of the tongue (1%). 12884236 Human
brca1 leukoplakia The percentage positivity of BRCA1 expression in tongue cancer patients was significantly lower (34%), as compared with patients with leukoplakia (100%; P = 0.000001). 12884236 Human
brca1 tongue cancer The percentage positivity of BRCA1 expression in tongue cancer patients was significantly lower (34%), as compared with patients with leukoplakia (100%; P = 0.000001). 12884236 Human
brca1 carcinoma in situ of the breast Ninety-five per cent of the epithelial ovarian cancers occurred in BRCA1 mutation carrying women versus 38% of infiltrating breast cancers and 7% of carcinoma in situ of the breast. 11334729 Human
brca1 in situ breast cancers We investigated invasive and/or in situ breast cancers from 30 women with deleterious BRCA1/2 mutations and unclassified variant BRCA1/2 alterations. 14520695 Human
brca1 radiation-induced cancer (5) The ratio of the risk of radiation-induced cancer in relatives to that in unrelated individuals in the population increases with the biological relatedness of the relative, being higher for close than for distant relatives; however, even when the muta 11604087 Human
brca1 radiation-induced cancer Using an autosomal dominant model of cancer predisposition and radiosensitivity developed earlier and applying it to breast cancer risks associated with mutations in the BRCA1 gene, we show that: (1) The risk ratio (i.e. the ratio of risk of radiation-ind 9588361 Human
brca1 radiation-induced cancers We also discuss the use of a Mendelian one-locus, two-allele autosomal dominant model for predicting the impact of cancer predisposition and increased radiosensitivity on the risk of radiation-induced cancers in the population and in relatives of affected 11604087 Human
brca1 nsclc 5-Aza-2'-deoxycytidine treatment of NSCLC cells showed demethylation and reexpression of the BRCA1 and BRCA2 genes and reduced anchorage-independent growth. 17289874 Human
brca1 squamous cell carcinoma CONCLUSIONS: Our retrospective study provides compelling evidence that low mRNA and protein expression in the BRCA1/BRCA2 and XRCC5 genes occur in lung adenocarcinoma and squamous cell carcinoma, respectively, and that promoter hypermethylation is the pre 17289874 Human
brca1 squamous cell carcinoma RESULTS: The data indicated that low protein expression of BRCA1 and BRCA2 was frequent in lung adenocarcinomas (42-44%), whereas low XRCC5 protein expression was more prevalent among squamous cell carcinoma (32%). 17289874 Human
brca1 lung adenocarcinoma CONCLUSIONS: Our retrospective study provides compelling evidence that low mRNA and protein expression in the BRCA1/BRCA2 and XRCC5 genes occur in lung adenocarcinoma and squamous cell carcinoma, respectively, and that promoter hypermethylation is the pre 17289874 Human
brca1 breast tumours We suggest that these altered CTCF and DNMT3b expression patterns represent (a) critical events responsible for the epigenetic inactivation of BRCA1 and (b) a diagnostic signature for epigenetic inactivation of other tumour suppressor genes in sporadic br 17071074 Human
brca1 li-fraumeni cancer syndrome METHODS: Data from 65 individuals were analyzed; 24 members of Li-Fraumeni cancer syndrome families were tested for p53 mutations (all 24 were unaffected), and 41 subjects with hereditary breast-ovarian cancer susceptibility were tested for BRCA1 mutation 10811679 Human
brca1 invasive lobular cancers Immunohistochemical staining of human breast specimens also revealed BRCA1 nuclear foci in benign breast, invasive lobular cancers and low-grade ductal carcinomas. 9988281 Human
brca1 serous surface carcinoma Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. 10029450 Human
brca1 diamond blackfan anemia The 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic sho 16121806 Human
brca-1 benign tumours This elevated expression of Brn-3b is not found in normal mammary cells, benign tumours or in malignant tumour samples which do not exhibit reduced levels of BRCA-1. 10597274 Human
brca-1 gorlin syndrome Allele-discriminating oligonucleotide probes in conjunction with RCA also were used to discriminate wild-type and mutant alleles in the cystic fibrosis transmembrane conductance regulator, p53, BRCA-1, and Gorlin syndrome genes in the nuclei of cultured c 11274414 Human
brca-1 gynecologic cancer Bilateral oophorectomy has the potential of reducing the risk of both breast and gynecologic cancer in women carrying BRCA-1 or BRCA-2 mutations. 15646397 Human
brca1 squamous cell carcinomas of the esophagus Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus. 7907942 Human
brca1 hereditary breast and ovarian cancer We have examined 22 families with at least one case of male breast cancer for linkage to the hereditary breast and ovarian cancer locus, BRCA1, on chromosome 17q. 8075631 Human
brca1 ovarian tumors The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. 7939630 Human
brca1 colorectal tumours A number of known or putative tumour-suppressor genes including NF1, BRCA1, NME1, NME2 and prohibitin are present on the long arm of chromosome 17, and this region has not been extensively analysed in colorectal tumours. 7734302 Human
brca1 laryngeal tumours In addition, BRCA1 TSG is implicated in the development of laryngeal tumours. 7585472 Human
brca1 prostate tumor We wished to test the frequency of BRCA1 deletion and that of other markers in the region of proximal 17q in prostate tumor cells. 8558713 Human
brca1 prostate tumors MATERIALS AND METHODS: We used a dual-color fluorescence in situ hybridization (FISH) assay using P1 phage probes for the BRCA1 gene and 3 flanking sites at 17q12-21, as well as a chromosome 17 centromere-specific alpha-satellite probe, to detect deletion 8558713 Human
brca1 benign breast tumours For BRCA1 (D17S855, THRA1, D17S579) losses could be detected in invasive ductal carcinoma (IDC; n = 108) in 32-38%, invasive lobular carcinoma (ILC; n = 19) in 21-42% depending on the marker applied, but not in benign breast tumours (n = 15). 8630282 Human
brca1 hamartomas To investigate the molecular mechanisms of tuberous sclerosis (TSC) histopathologic lesions, we have tested for loss of heterozygosity the two TSC loci (TSC1 and TSC2) and seven tumor suppressor gene-containing regions (TP53, NF1, NF2, BRCA1, APC, VHL, an 8824721 Human
brca1 cowden syndrome The gene for Cowden syndrome has recently been located and it will now be possible to assess whether it is responsible for the set of families not accounted for by BRCA1 and BRCA2. 8875258 Human
brca1 prostate tumor BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. 9662340 Human
brca1 prostate tumor These findings suggest that BRCA1 may function as a human prostate tumor suppressor by virtue of its ability to modulate proliferation and various components of the cellular damage response. 9662340 Human
brca1 prostate tumor They also suggest several potential target gene products for a BRCA1 prostate tumor suppressor function. 9662340 Human
brca1 high grade tumors LOH of BRCA1 correlated with high grade tumors (p=0.0005) and negative hormone receptors (p=0.01). 9735416 Human
brca1 necrosis RESULTS: Breast carcinoma in BRCA1 mutation carriers was associated with a distinct histologic appearance; these tumors were high grade, and had exceptionally high mean mitotic counts, a syncytial growth pattern, pushing margins, and confluent necrosis. 9840533 Human
brca1 proliferative breast disease The increased incidence of proliferative breast disease (PBD), associated with an increased risk of developing breast cancer and the identification of the BRCA1 and BRCA2 breast cancer susceptibility genes have provided the opportunity for identification 9891229 Human
brca1 cowden's disease The main susceptibility genes are BRCA1 and BRCA2, but others include Cowden's disease, Li Fraumeni syndrome and ataxia-telangiectasia. 10665131 Human
brca1 cystadenomas BRCA1 expression was highly correlated with MIB-1 expression in cystadenomas and borderline tumors. 10684699 Human
brca1 uterine tumors Loss of heterozygosity analysis found loss of the wild-type BRCA1 allele in the primary uterine tumors. 10862837 Human
brca1 inclusion cysts METHODS: Ovarian tissues from 18 BRCA1 heterozygotes and from 20 age-matched controls were examined in a blinded fashion for histologic evidence of surface epithelial pseudostratification, epithelial inclusion cysts, deep cortical invaginations of surface 10918170 Human
brca1 sertoli cell tumor To gain an understanding of the molecular mechanisms of ovarian cancer, we analyzed 16 ovarian tumors from Jewish Israeli patients by comparative genomic hybridization: 12 invasive epithelial tumors (including three BRCA1 and one BRCA2 mutation carriers), 10958937 Human
brca1 brain tumour Inclusion criteria were 1. family history of breast cancer; 2. absence of germline BRCA1 and p53 mutation; and 3. at least one case of brain tumour (glioblastoma, meningioma, or medulloblastoma) in either the index case or one of their first or second deg 10371336 Human
brca1 medulloblastoma Inclusion criteria were 1. family history of breast cancer; 2. absence of germline BRCA1 and p53 mutation; and 3. at least one case of brain tumour (glioblastoma, meningioma, or medulloblastoma) in either the index case or one of their first or second deg 10371336 Human
brca1 intestinal tumor Only MIN/+ F1 females developed mammary tumors and heterozygosity for a mutant Brca1 or ATM allele had no effect on mammary or intestinal tumor incidence and multiplicity. 11181458 Human
brca1 hodgkin's disease Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. 11173152 Human
brca1 hodgkin's disease In the Hodgkin's disease group, LOH was observed in 30% of tumors at BRCA1 and 10% of tumors at BRCA2 vs. 10% and 0% of tumors in the control group at BRCA1 and BRCA2, respectively. 11173152 Human
brca1 hodgkin's disease CONCLUSION: We were unable to find statistical evidence for LOH at BRCA1 and BRCA2 in breast cancers from patients previously irradiated for Hodgkin's disease. 11173152 Human
brca1 prostate tumors A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1. 11170749 Human
brca1 prostate tumors In previous work from our laboratory, one or more deleted regions were found in prostate tumors distal to the breast and ovarian cancer susceptibility gene (BRCA1) on chromosome 17. 11170749 Human
brca1 prostate tumors The analysis of prostate tumors indicated an 85-kb novel commonly deleted interval flanked by D17S1184-D17S183-D17S1203-D17S1860, which is at least 470 kb distal to the BRCA1 gene. 11170749 Human
brca1 prostate tumor These activities are consistent with a putative prostate tumor suppressor function of BRCA1. 11405179 Human
brca1 infiltrating cancer Presence of BRCA1 mutation was associated with infiltrating cancer, high grade and lack of oestrogen receptor (p < 0.05 for all 3 characteristics). 12237897 Human
brca1 head-and-neck cancer Molecular epidemiological studies revealed characteristic BRCA1 mutation patterns of familiar breast cancer and DNA repair enzyme polymorphism in head and neck cancer. 12563351 Human
brca1 hbl The characterization of 6 anti-BRCA1 antibodies revealed a BRCA1 200-kDa protein detected in breast cell lines (MDA-MB 231, HBL 100, T-47D and MCF7) or in an acute leukemia (MOLT 4), known to overexpress BRCA1. 12680164 Human
brca1 lymphoid neoplasm The observation of a germline BRCA1 mutation in an index case with a lymphoid neoplasm in the setting of a family history of breast cancer prompted us to explore the role of BRCA germline mutations as lymphoma susceptibility alleles. 12691152 Human
brca1 colorectal tumour Since promoter methylation is a direct cause of transcription silencing of the BRCA1 gene in approximately 10-20% of human breast cancer we further investigated its promoter methylation status in ten primary colorectal tumour samples, but revealed no evid 12802093 Human
brca1 benign tumours The majority of benign tumours, and more especially of malignant tumours, showed a significant reduction in the nuclear expression of BRCA1 protein and an increase in cytoplasmic expression. 12834609 Human
brca1 hbl We investigated the effects of resveratrol on BRCA1 and BRCA2 expression in human breast cancer cell lines (MCF7, HBL 100 and MDA-MB 231) using quantitative real-time RT-PCR, and by perfusion chromatography of the proteins. 12838319 Human
brca1 glioblastomas Together with the evidence that H2AX transfection does not affect growth activities of non-tumor cells under genotoxic stimuli, this suggests that H2AX gene transfer would provide a new modality for radio-chemotherapy for glioblastomas, probably through o 12851679 Human
brca1 carcinoma of the tongue BRCA1 expression in leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 carcinoma of the tongue BACKGROUND AND OBJECTIVES: Expression of BRCA1 was examined in patients with leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 carcinoma of the tongue Cytoplasmic staining of BRCA1 was observed in both leukoplakia and carcinoma of the tongue. 12884236 Human
brca1 carcinoma of the tongue In carcinoma of the tongue, only 34% of the patients showed BRCA1 expression. 12884236 Human
brca1 squamous cell carcinoma of the tongue Moreover, BRCA1 expression with a staining intensity of 2+ was significantly higher in patients with dysplasia (50%) than in those with hyperplasia (33%), followed by patients with squamous cell carcinoma of the tongue (1%). 12884236 Human
brca1 tongue tumors CONCLUSIONS: Subcellular localization of the BRCA1 gene product provided evidence of its involvement in the pathogenesis of tongue tumors. 12884236 Human
brca1 hodgkin's disease Young women who are at a potential high-risk of developing breast cancer such as those with germline mutations of BRCA1, BRCA2, TP53, PTEN or who have previously received mantle irradiation for Hodgkin's disease need close follow-up and are candidate 14642925 Human
brca1 in-situ carcinoma The frequency of proliferative lesions of the tubal epithelium, including in situ carcinoma, appears to be increased in BRCA1 mutation carriers. 14668548 Human
brca1 hodgkin's disease TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. 14673037 Human
brca1 benign tumours Decreased expression of BRCA1 was found in 16% of benign tumours, 38% of borderline tumours, and 72% of carcinomas. 14743504 Human
brca1 borderline tumours Decreased expression of BRCA1 was found in 16% of benign tumours, 38% of borderline tumours, and 72% of carcinomas. 14743504 Human
brca1 benign tumours LOH of BRCA1 was demonstrated in no benign tumours, 15% of borderline tumours, and 66% of carcinomas. 14743504 Human
brca1 borderline tumours LOH of BRCA1 was demonstrated in no benign tumours, 15% of borderline tumours, and 66% of carcinomas. 14743504 Human
brca1 borderline tumours Methylation of BRCA1 was not detected in benign or borderline tumours, but was present in 31% of carcinomas. 14743504 Human
brca1 nsclc Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. 14647419 Human
brca1 uterine tumors Loss of heterozygosity analysis found a loss of the wild-type BRCA1 allele in three of the four primary uterine tumors that were examined. 14766242 Human
brca1 prostate tumor EXPERIMENTAL DESIGN: The expression of 16 AR coactivators and corepressors (SRC1, beta-catenin, TIF2, PIAS1, PIASx, ARIP4, BRCA1, AIB1, AIB3, CBP, STAT1, NCoR1, AES, cyclin D1, p300, and ARA24) was measured in prostate cancer cell lines, xenografts, and c 14871982 Human
brca1 fibrocystic breast The purpose of this study was to demonstrate the effects of lycopene, the major tomato carotenoid, on the expression of the BRCA1 and BRCA2 genes in three breast tumour cell lines, MCF-7, HBL-100, MDA-MB-231 and the fibrocystic breast cell line MCF-10a. 15251168 Human
brca1 cancer A significant increase in the cancer risk associated either with harboring one additional putative high-risk NHEJ genotype or with the joint effect of having reproductive risk factors (reflected by an interval of > or =12 years between menarche and first 15256476 Human
brca1 wilms tumor Such a gene might be observed in families, as has been documented in familial breast cancer (BRCA1/2), familial colorectal cancer (HNPCC), retinoblastoma (RB1), and Wilms tumor (WT1). 15264274 Human
brca1 astrocytoma RESULTS: Seventeen genes (ABL, APC, APAF1, BRCA1, CSPG2, DAPK1, hMLH1, LKB1, PTEN, p14ARF, p15INK4b, p27KIP1, p57KIP2, RASSF1C, RB1, SURVIVIN, and VHL) displayed a uniformly unmethylated pattern in all the astrocytoma and non-astrocytoma tissues examined. 15367334 Human
brca1 serous adenocarcinomas RESULTS: Tumors in BRCA1 mutation carriers were more likely than tumors in age-matched controls to be invasive serous adenocarcinomas (odds ratio, 1.84; 95% confidence interval, 1.21-2.79) and unlikely to be borderline or mucinous tumors. 15073127 Human
brca1 mucinous tumors RESULTS: Tumors in BRCA1 mutation carriers were more likely than tumors in age-matched controls to be invasive serous adenocarcinomas (odds ratio, 1.84; 95% confidence interval, 1.21-2.79) and unlikely to be borderline or mucinous tumors. 15073127 Human
brca1 pancreatic adenocarcinoma Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. 15173085 Human
brca1 pancreatic adenocarcinoma EXPERIMENTAL DESIGN: To study a potential correlation of BRCA1 and BRCA2 to chronic pancreatitis and development of sporadic pancreatic adenocarcinoma, we have analyzed the expression of these genes by quantitative PCR and performed immunohistochemical an 15173085 Human
brca1 pancreatic adenocarcinoma CONCLUSIONS: Our data demonstrate alteration of BRCA1 expression in chronic pancreatitis and sporadic pancreatic adenocarcinoma. 15173085 Human
brca1 lung cancer BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. 15317748 Human
brca1 lung cancer BRCA1 plays a central role in DNA repair, and decreased BRCA1 mRNA expression in the human breast cancer HCC1937 cell line caused cisplatin hypersensitivity, but the relation between BRCA1 and survival in lung cancer patients has never been examined. 15317748 Human
brca1 non-small-cell lung cancer We used real-time quantitative polymerase chain reaction to determine BRCA1 mRNA levels in 55 surgically resected tumors of non-small-cell lung cancer patients who had received neoadjuvant gemcitabine/cisplatin chemotherapy, and divided the gene expressio 15317748 Human
brca1 lung cancer BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer. 15317748 Human
brca1 borderline ovarian tumors Although the incidence of borderline ovarian tumors may not be increased in HBOC syndrome kindreds and those who carry cancer-associated BRCA1 and BRCA2 mutations, these individuals could be susceptible to malignant transformation of borderline lesions of 15516851 Human
brca1 metastasis to the peritoneum Moreover, recent reports raise the question of possibly increased risk in Jewish carriers of germline BRCA1 mutations for uterine papillary serous carcinoma, which could be the source of metastasis to the peritoneum in some cases. 15516851 Human
brca1 uterine papillary serous carcinoma Moreover, recent reports raise the question of possibly increased risk in Jewish carriers of germline BRCA1 mutations for uterine papillary serous carcinoma, which could be the source of metastasis to the peritoneum in some cases. 15516851 Human
brca1 peritoneal carcinomatosis Prophylactic oophorectomy has been found to reduce the risk for ovarian cancer in women from HBOC kindreds and those who carry cancer-associated BRCA1 and BRCA2 mutations, leaving a residual risk for peritoneal carcinomatosis of well less than 5%. 15516851 Human
brca1 familial cancer METHODS: Seventy women with a BRCA1/BRCA2 mutation recruited from familial cancer risk clinics participated in 12 sessions of supportive-expressive group therapy that lasted 6 months. 15478194 Human
brca1 borderline tumours BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. 15477862 Human
brca1 borderline tumours Odds ratios (OR) of developing ovarian cancer and borderline tumours in the presence of BRCA1 mutations and CA125 level were derived from conditional logistic regression models. 15477862 Human
brca1 borderline tumours Among the 478 ovarian cancer patients, 19 BRCA1 mutations were identified (1675delA, 1135insA, 816delGT and 3347delAG), none among the patients with borderline tumours. 15477862 Human
brca1 ovarian cancer Among the 478 ovarian cancer patients, 19 BRCA1 mutations were identified (1675delA, 1135insA, 816delGT and 3347delAG), none among the patients with borderline tumours. 15477862 Human
brca1 ovarian cancer This study showed that BRCA1 mutation carriers have a very high risk of ovarian cancer. 15477862 Human
brca1 invasive cancers We estimated mutation carrier prevalence in U.S. non-Hispanic Whites, specific for Ashkenazi status, using data from two population-based series of San Francisco Bay Area patients with invasive cancers of the breast or ovary, and data on breast and ovaria 15598764 Human
brca1 ovarian cancer OBJECTIVE: To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk. 15589605 Human
brca1 stage-ii breast cancer PATIENTS AND METHODS: Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. 15589605 Human
brca1 invasive cancers However, the prevalence of BRCA1 mutations among non-Ashkenazi Whites is uncertain. 15598764 Human
brca1 tumor In addition to improving tumor classification, gene expression signatures have been identified which are related to BRCA1 and BRCA2 mutation status, ER status, and patient prognosis. 15687694 Human
brca1 ductal carcinoma in situ Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ. 15728167 Human
brca1 breast carcinoma CONTEXT: The distribution of BRCA1 and BRCA2 mutations in women diagnosed with noninvasive breast carcinoma is unknown. 15728167 Human
brca1 dcis MAIN OUTCOME MEASURES: Prevalence of disease-associated mutations of BRCA1 and BRCA2 in women diagnosed with DCIS. 15728167 Human
brca1 dcis RESULTS: Three (0.8%) and 9 (2.4%) of 369 DCIS cases had disease-associated mutations in BRCA1 or BRCA2, respectively. 15728167 Human
brca1 invasive breast cancer CONCLUSIONS: Ductal carcinoma in situ is a part of the breast/ovarian cancer syndromes defined by BRCA1 and BRCA2, with mutation rates similar to those found for invasive breast cancer. 15728167 Human
brca1 mucinous carcinomas Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands wit 15761464 Human
brca1 endometrioid carcinomas Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands wit 15761464 Human
brca1 serous cystadenomas Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional brca1 in ovarian granulosa cells. 15797026 Mouse
brca1 gynecological cancers Given that ovulatory activity is a strong risk factor for sporadic ovarian cancer, we hypothesized that reduced BRCA1 expression might predispose to gynecological cancers indirectly, by influencing ovarian granulosa cells. 15797026 Mouse
brca1 cystic tumors Here, we show that indeed, inactivation of the Brca1 gene in granulosa cells led to the development of cystic tumors in the ovaries and uterine horns. 15797026 Mouse
brca1 lobular carcinoma in situ Risk was defined as either (a) 5-year Gail risk calculation > or = 1.7%; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. 15824145 Human
brca1 atypical hyperplasia Risk was defined as either (a) 5-year Gail risk calculation > or = 1.7%; (b) prior biopsy exhibiting atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ; or (c) known BRCA1/2 mutation carrier. 15824145 Human
brca1 carcinomatosis Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. 15863145 Human
brca1 carcinomatosis This study was undertaken to examine and report particularly the occurrence of intra-abdominal carcinomatosis, as well as other cancers, following prophylactic oophorectomy in patients who carry cancer susceptibility mutations of BRCA1 and BRCA2 and to as 15863145 Human
brca1 carcinomatosis All five cases of intra-abdominal carcinomatosis were serous carcinomas, and all occurred in BRCA1 mutation carriers. 15863145 Human
brca1 carcinomatosis CONCLUSIONS: Intra-abdominal carcinomatosis in our series was diagnosed only in BRCA1 mutation carriers. 15863145 Human
brca1 breast cancer Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. 15802279 Human
brca1 mammary adenocarcinomas Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRC 15750629 Mouse
brca1 hyperplasias Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERalpha expression 15750629 Mouse
brca1 hemangioblastoma The 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic sho 16121806 Human
brca1 breast adenocarcinoma The semi-quantitative PCR-based assay was used to determine the lesion frequencies produced by carboplatin in the 696-bp fragment of the 3'-region of BRCA1 gene and in the 3,426-bp fragment of the BRCA1 exon 11 of human breast adenocarcinoma MCF-7 ce 16099593 Human
brca1 colon tumor BRCA1 and BRCA2 mRNAs expressions were altered according to colon tumor site: BRCA1 3' and BRCA2 3' mRNAs levels were highest, respectively, in the right colon and left colon. 16158938 Human
brca1 medullary breast carcinoma A total of 3 mutations in BRCA1 were identified among 14 (21.4%) women with a medullary breast carcinoma. 16168118 Human
brca1 lung adenocarcinomas RESULTS: The data indicated that low protein expression of BRCA1 and BRCA2 was frequent in lung adenocarcinomas (42-44%), whereas low XRCC5 protein expression was more prevalent among squamous cell carcinoma (32%). 17289874 Human
brca1 lung cancer Anchorage-dependent growth after reexpression of these genes was examined in a lung cancer cell line that originally lacked BRCA1 and BRCA2 expression. 17289874 Human
brca1 nsclc PATIENTS AND METHODS: We examined the loss of protein and mRNA expression and the 5'CpG hypermethylation and allelic imbalance of the BRCA1, BRCA2, and XRCC5 genes in 98 non-small cell lung cancer (NSCLC) samples. 17289874 Human
brca1 non-small cell lung cancer PATIENTS AND METHODS: We examined the loss of protein and mRNA expression and the 5'CpG hypermethylation and allelic imbalance of the BRCA1, BRCA2, and XRCC5 genes in 98 non-small cell lung cancer (NSCLC) samples. 17289874 Human
brca1 lung adenocarcinoma In addition, low BRCA1 expression was significantly associated with low RB expression, especially in lung adenocarcinoma. 17289874 Human
brca1 sarcoma In this study, 23 unrelated individuals from families with one case of sarcoma and at least one case of breast cancer were screened for mutations in the TP53, BRCA1 and BRCA2 genes. 17224268 Human
brca1 metastatic bladder cancer PATIENTS AND METHODS: Messenger RNA expression levels of excision repair cross complementing 1 (ERCC1), breast cancer 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and caveolin-1 were determined by RT-PCR in tumor DNA from 57 advanced and metastat 17229776 Human
brca1 wilms' tumor Examples include the RB1 gene for retinoblastoma; the WT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tu 8741802 Human
brca1 ovarian cancer Mutations in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast/ovarian cancer, whereas mutations in BRCA2 account for a comparable percentage of inherited breast cancer cases. 8841191 Human
brca1 stage ii breast cancers Prior to BRCA1 analysis, 79 breast and 19 ovarian tumours from 57 breast and breast-ovarian cancer families, and 170 tumours from a comparison group of stage II breast cancers were studied with regard to histopathological features; immunohistochemistry [c 9155518 Human
brca1 squamous cell carcinoma In order to investigate the implication of these novel TSGs in the development of laryngeal neoplasia we performed a loss of heterozygosity (LOH) analysis using a bank of 15 polymorphic microsatellite markers (4 at 8p21, 7 at 9p21 arm and 4 at 17q arm sur 9930365 Human
brca1 ovarian epithelial tumors (oets) OBJECTIVE: The purpose of this study was to examine BRCA1 expression and its relationship to cell proliferation in sporadic ovarian epithelial tumors (OETs). 10684699 Human
brca1 ovarian epithelial tumors This study evaluated 34 formalin-fixed, paraffin-embedded ovarian epithelial tumors for LOH by polymerase chain reaction (PCR) for the following microsatellite markers: TP53(17p13.1/p53 gene), D17S579(17q/BRCA1 gene), and ESR (6q24-27/estrogen receptor ge 10685639 Human
brca1 clear cell carcinoma Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. 10749023 Human
brca1 clear cell carcinoma We report the case history of a patient with a family history of breast and ovarian cancer who was subsequently found to be a carrier of the BRCA1 gene, in whom a tiny focus of clear cell carcinoma was found at the fimbrial end of one fallopian tube when 10749023 Human
brca1 adrenal tumors Adrenal tumors in BRCA1/BRCA2 mutation carriers. 11169568 Human
brca1 medullary thyroid carcinoma At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
brca1 nevoid basal cell carcinoma syndrome Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. 11231326 Human
brca1 medullary carcinomas All BRCA1 mutation-associated BC corresponded to infiltrating ductal carcinomas (20% medullary carcinomas) with a more aggressive pathological behavior. 11481082 Human
brca1 ovarian serous papillary cancer (ospc) The aim of the study was to examine the prevalence of primary peritoneal serous papillary carcinoma (PPSPC) as compared with ovarian serous papillary cancer (OSPC), and to study the clinicopathologic features and the frequency of germline BRCA1 and BRCA2 11737473 Human
brca1 primary peritoneal serous papillary carcinoma (ppspc) The aim of the study was to examine the prevalence of primary peritoneal serous papillary carcinoma (PPSPC) as compared with ovarian serous papillary cancer (OSPC), and to study the clinicopathologic features and the frequency of germline BRCA1 and BRCA2 11737473 Human
brca1 uterine papillary serous carcinoma (upsc) The purpose of the study was to examine BRCA1 germline mutation and its relationship to BRCA1 expression in two patients, a mother and a daughter, both diagnosed with uterine papillary serous carcinoma (UPSC). 11766733 Human
brca1 ovarian malignancies Although BRCA1 functions as a tumor suppressor gene, conflicting studies have shown that BRCA1 dysfunction alone may not be sufficient for tumorigenesis. p53 is a tumor suppressor gene found to be dysfunctional in nearly 50% of all human cancers and in up 12063435 Human
brca1 osteosarcoma In this study, we monitored the activities of three members of the MAPK family (ERK1/2, JNK, p38) in MCF-7 breast cancer cells and U2OS osteosarcoma cells after their exposure to a recombinant adenovirus expressing wild type BRCA1 (Ad.BRCA1). 12082091 Human
brca1 ewing's sarcoma Because BARD1 associates via its NH2-terminal RING domain with the breast cancer susceptibility gene BRCA1 that provides a platform for interactions with proteins involved in DNA repair and checkpoint control, our results provide a link between the Ewing& 12183411 Human
brca1 myoma [Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen] OBJECTIVE: To report the case of significant growth of a myoma in a premenopausal woman with a suspicion of B 12457141 Human
brca1 mouse tumors Mammary (and other) tumors occur at long latency as compared to oncogene-induced mouse tumors. p53 deficiency is highly cooperative with both Brca1 and Brca2 in promoting tumorigenesis. 12483515 Mouse
brca1 proliferative fibrocystic changes (pfc) RESULTS: The 28 women from the unilateral cohort with deleterious BRCA1/2 mutations had a lower prevalence of proliferative fibrocystic changes (PFC) (7%) compared with their matched control group (25%) (P = 0.075) and with patients who had a family histo 12491499 Human
brca1 tumor There was a trend in favor of a worse prognosis for women who carried a germline BRCA1 mutation and whose tumor overexpressed p53. 12548593 Human
brca1 head and neck cancer Molecular epidemiological studies revealed characteristic BRCA1 mutation patterns of familiar breast cancer and DNA repair enzyme polymorphism in head and neck cancer. 12563351 Human
brca1 cml BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. 12576338 Human
brca1 sarcoma Other families with sarcoma had hereditary nonpolyposis colorectal carcinoma with MSH2 mutation, hereditary breast carcinoma with BRCA1 mutation, and p53 mutation in a Li-Fraumeni syndrome. 14584079 Human
brca1 stage ii breast cancer PATIENTS AND METHODS: Patients included 491 women with stage I or stage II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. 15197194 Human
brca1 stage ii breast cancer PATIENTS AND METHODS: Patients were 491 women with stage I or stage II breast cancer, diagnosed from 1975 to 2000 and for whom a BRCA1 or BRCA2 mutation had been identified. 15589605 Human
brca1 ductal carcinoma in situ (dcis) OBJECTIVE: To estimate the BRCA1 and BRCA2 mutation prevalence in women with ductal carcinoma in situ (DCIS), unselected for age, family history, or ethnicity. 15728167 Human
brca1 lung cancer Organ-specific differences in epidermal growth factor receptor (EGFR) mutational spectra and frequencies were found in lung cancer and sporadic and BRCA1/2-related breast cancers. 15841079 Human
brca1 gastric cancer [Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients] To investigate microsatellite instability (MSI) and loss of heterozygosity (LOH) of locus D17S396, D17S579 and D17S855, and their effect on the expression of nm23H1 and BRCA1 16011248 Human
brca1 sporadic colon cancer By comparison, LOH mostly arises in the late period of sporadic colon cancer and endows a high aggressive and poor prognostic phenotype. nm23H1 protein could effectively restrain gastric cancer metastasis and development; and BRCA1 protein could restain t 16011248 Human
brca1 carcinomatosis Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". 16188301 Human
brca1 ovarian adenocarcinomas METHODS: The involvement of STRAD in 42 PJS associated tumours (sporadic lung, colon, gastric, and ovarian adenocarcinomas) was studied using loss of heterozygosity (LOH) analysis of eight microsatellite markers on chromosome 17, including TP53, BRCA1, an 16189157 Human
brca1 laryngeal cancers In addition, common mutations/variants in the 3 genes BRCA1, NOD2 and CYP1B1, known to be associated with early-onset breast cancer, were assessed to determine their frequency in 348 unselected laryngeal cancers. 16331346 Human
brca1 gynecological cancer The correlation between BRCA1 and E7 of papilloma virus becomes a new interesting topic in gynecological cancer. 16598475 Human
brca1 diffuse large b-cell lymphoma SNPs in four genes (ERCC5, ERCC2, WRN, and BRCA1) were associated with altered risk of NHL and diffuse large B-cell lymphoma (DLBCL), the major B cell subtype. 16738949 Human
brca1 dlbcl SNPs in four genes (ERCC5, ERCC2, WRN, and BRCA1) were associated with altered risk of NHL and diffuse large B-cell lymphoma (DLBCL), the major B cell subtype. 16738949 Human
brca1 nhl SNPs in four genes (ERCC5, ERCC2, WRN, and BRCA1) were associated with altered risk of NHL and diffuse large B-cell lymphoma (DLBCL), the major B cell subtype. 16738949 Human
brca1 mouse mammary tumor However, a report published in a recent issue of the International Journal of Biological Sciences revealed that PARP-1 inhibitors, although able to kill naïve BRCA1 mutant cells with high specificity both in vitro and in vivo, exhibit minimal specificity 16906222 Human
brca1 medullary carcinoma of breast Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1. 16945238 Human
brca1 medullary carcinoma of breast This report describes identification of a mutation in BRCA1 gene using protein truncation (PTT) assay in a patient with medullary carcinoma of breast who also had a family history of breast cancer. 16945238 Human
brca 1 werner's syndrome Examples of molecules that may have a role in the repair of telomeric DNA prior to replicative senescence include ATM, p53, PARP, DNA-PK, Ku70/80, the human hRad50-hMre11-p95 complex, BRCA 1 and 2 and the helicases implicated in Bloom's and Werner&ap 10989122 Human
brca-1 glioblastoma multiforme Multicentric Glioblastoma Multiforme in a Patient with BRCA-1 Invasive Breast Cancer. 16958968 Human
brca-1 ductal adenocarcinoma We report the case of a 46-year-old woman previously treated for ductal adenocarcinoma of the breast with BRCA-1 who subsequently was diagnosed with multicentric glioblastoma multiforme (GBM) in the right temporal and right occipital lobes. 16958968 Human
brca-1 glioblastoma multiforme We report the case of a 46-year-old woman previously treated for ductal adenocarcinoma of the breast with BRCA-1 who subsequently was diagnosed with multicentric glioblastoma multiforme (GBM) in the right temporal and right occipital lobes. 16958968 Human
brca-1 glial tumors We briefly discuss the incidence of BRCA-1 mutations in breast cancer as well as other primary neoplasms and consider potential mechanisms shared in the pathogenesis of breast and glial tumors. 16958968 Human
brca1 non-small cell lung cancer Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. 17289874 Human
brca1 lung cancer We postulated that alterations of the double-strand break repair genes (BRCA1, BRCA2, and XRCC5) might be involved in lung cancer. 17289874 Human
brca1 invasive carcinoma Preliminary microarray comparisons on DCIS and invasive carcinoma samples dissected from formalin-fixed paraffin sections showed a consistent downregulation of two previously identified FHIT-related genes, caspase 1 and BRCA1 in lesions underexpressing FH 17164758 Human
brca1 promyelocytic acute leukaemia Another important locus which is involved in oncogenic processes is locus RARA--the receptor of retinoic acid which participates in the formation of promyelocytic acute leukaemia and locus BRCA1 the pathogenic alleles of which are a dominant predispositio 7553759 Human
brca1 early stage breast cancer The mapping and cloning of genes important in familial breast cancers (eg BRCA1) have provided the essential tools for pinpointing the genes that may be critical in early stage breast cancer as well as for developing genetic tests for predicting carrier s 8718525 Human
brca1 atypical medullary carcinoma Medullary or atypical medullary carcinoma was, however, found more often in BRCA1 (13%, p < 0.0001) than in BRCA2-mutation carriers (3%) or controls (2%). 9167459 Human
brca1 typical medullary breast carcinoma (tmc) To explore a possible relationship between this phenotype and BRCA1 mutations, we first compared 32 BRCA1-BCs and 200 consecutive cases of breast cancer without familial history for the prevalence of typical medullary breast carcinoma (TMC) using the crit 9563465 Human
brca1 atypical medullary carcinoma Atypical medullary carcinoma was overrepresented in BRCA1 mutation carriers. 9840533 Human
brca1 low grade tumors All low grade tumors and tumors with low mitotic rates belonged to the group without BRCA1 or BRCA2 mutations. 9840533 Human
brca1 invasive mucinous carcinomas We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular ca 9872332 Human
brca1 lobular carcinomas in situ We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular ca 9872332 Human
brca1 primary peritoneal carcinoma Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes. 10029436 Human
brca1 peritoneal serous papillary carcinoma At least 3 of the patients with peritoneal serous papillary carcinoma carry BRCA1 185delAG mutations. 10203660 Human
brca1 lymph node metastases LOH in the BRCA1 region was found in 47% of tumors, correlating significantly with estrogen receptor content (p = 0.025), progesterone receptors (p = 0.004), higher grade (p = 0.0008), peritumoral vessel invasion (p = 0.001), and lymph node metastases (p 10206068 Human
brca1 lymph node metastases Concomitant losses in the BRCA1 and BRCA2 regions were found in 32% of cases, correlating significantly with lymph node metastases (p = 0.0002), estrogen receptor content (p = 0.003), progesterone receptors (p = 0.001), histologic grade (p = 0.01), and pe 10206068 Human
brca1 breast ovarian cancer syndrome The high frequencies of breast ovarian cancer syndrome, serous adenocarcinoma, high histological grades, advanced FIGO stages, and breast cancer as double cancer were found to be characteristic of ovarian cancer with germline mutations in BRCA1. 10634513 Human
brca1 atypical medullary carcinoma Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation. 10770566 Human
brca1 villoglandular adenocarcinomas Twelve well-differentiated villoglandular adenocarcinomas (WDVAs) of the uterine cervix were retrospectively analyzed for the presence and specific genotype of human papillomavirus (HPV), tumor suppressor loss (p53, MCC, APC, BRCA1), cancer gene mutation 10782406 Human
brca1 early onset breast cancer Mutations in breast cancer tumor susceptibility genes, BRCA1 and BRCA2, predispose women to early onset breast cancer and other malignancies. 10843985 Human
brca1 early onset breast carcinoma The authors undertook this study to determine the prevalence and spectrum of germline BRCA1 mutations among women in Singapore with early onset breast carcinoma. 10951344 Human
brca1 primary serous peritoneal carcinoma BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma. 11059339 Human
brca1 mouse mammary cancer Expression of Brca1 in mouse mammary cancer has yet to be analysed. 11077440 Human
brca1 primary peritoneal carcinoma Because of these histologic similarities, we postulated that, in some cases, UPSC may be a manifestation of a field defect in BRCA1 carriers, which also includes ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma. 11104623 Human
brca1 atypical medullary carcinoma An excess of medullary/atypical medullary carcinoma has been reported in patients with BRCA1 mutations. 11250680 Human
brca1 early stage breast cancer Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer. 11380364 Human
brca1 atypical duct hyperplasia Epithelial mammary cells transduced with full-length Brca1 developed normally, whereas those transduced with Brca1-Delta11 or Brca1-W1777Stop formed atypical duct hyperplasia associated with reduced branching. 11889595 Human
brca1 rat mammary carcinomas Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas. 12203372 Rat
brca1 rat mammary carcinomas In the present study, we demonstrate that immunoreactivity of Brca1 was reduced in almost all rat mammary carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), whereas hypermethylation of its promoter, mutations in its entire codin 12203372 Rat
brca1 pelvic cancers Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. 12228218 Human
brca1 lymph node metastasis In addition, loss of BRCA1 expression was also related to poor tumor differentiation and lymph node metastasis. 12552965 Human
brca1 sporadic colorectal cancer Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer. 14527905 Human
brca1 in situ carcinoma The frequency of proliferative lesions of the tubal epithelium, including in situ carcinoma, appears to be increased in BRCA1 mutation carriers. 14668548 Human
brca1 medullary cancer To test the feasibility of using these rare histological subtypes as an alternative to epidemiological factors, 42 cases of medullary cancer unselected for family history were screened for BRCA1 point mutations and large exon rearrangements. 15039599 Human
brca1 peritoneal papillary serous carcinoma (ppsc) Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. 15083174 Human
brca1 peritoneal papillary serous carcinoma These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. 15083174 Human
brca1 familial atypical multiple mole melanoma This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat 15264268 Human
brca1 mucinous cancers Only one of the individual genes studied, BRCA1, has a variable frequency of methylation that is significantly dependent on histologic pattern of tumor growth, with a higher frequency of methylation in mucinous cancers than ductal or lobular cancers. 15447983 Human
brca-1 peritoneal papillary serous adenocarcinoma Another patient with BRCA-1 mutation had unexpected widespread primary peritoneal papillary serous adenocarcinoma. 11812938 Human
brca1 brain metastases Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. 15972278 Human
brca1 breast cancer metastasis Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. 15972278 Human
brca1 cervical cancer Previously, we reported that BRCA1 strongly represses the transcriptional activity of estrogen receptor-alpha (ER-alpha) in human breast and prostate cancer cells but only weakly inhibits ER-alpha in cervical cancer cells. 15983032 Human
brca1 secondary cancers Heterozygous BRCA1 mutations predispose individuals to breast, ovarian and other secondary cancers. 16103751 Human
brca1 nsclc ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. 16169122 Human
brca1 non-small-cell lung cancer Aim of this explorative study was to determine the prognostic value of protein expression of the DNA damage repair enzymes ERCC1, hRad51, and BRCA1 for tumour response and survival of non-small-cell lung cancer patients treated with chemotherapy. 16169122 Human
brca1 non-small-cell lung cancer In conclusion, immunohistochemical staining of ERCC1, hRad51, and BRCA1, in tumour biopsies from non-small-cell lung cancer patients was not predictive for tumour response and survival after chemotherapy. 16169122 Human
brca1 hereditary ovarian carcinomas BACKGROUND: It is believed that BRCA1 and BRCA2 germline mutations account for the majority of hereditary ovarian carcinomas; however, to the authors' knowledge, there are scant data on the prevalence and spectrum of mutations, genotype/phenotype cor 16284991 Human
brca1 meningiomas However, methylation percentages for these genes were generally higher in a group of NF2-related meningiomas, with the exception of the BRCA1 gene. 16353169 Human
brca1 osteosarcoma To further explore the role of BRCA1 and p53 in repair of photoproducts, we eliminated wild type p53 from U2OS osteosarcoma cells and found that cyclobutane pyrimidine dimer (CPD) repair was markedly impaired following UV damage whereas repair of 6-4 phot 16357511 Human
brca1 lobular carcinoma in situ Exclusion criteria were an estimated lifetime risk < 20%, BRCA1/BRCA2 mutation, noninvasive carcinoma (ductal or lobular carcinoma in situ), and bilateral breast carcinoma. 16475207 Human
brca1 ductal carcinoma The BRCA1, APC, p16 and TIMP-3 genes were frequently methylated in ductal carcinoma (60.3, 58.6, 39.3 and 30.9%, respectively). 16537562 Human
brca1 mouse mammary tumors In a screen for gene copy number alterations in mouse mammary tumors initiated by loss of the Brca1 and Trp53 genes, we observed that the majority (11 of 15; 73%) had high-level amplification of wild-type Met, encoding a growth factor receptor implicated 16585167 Mouse
brca1 lung metastases This may relate in part to a different pattern of metastatic spread with in increased frequency of brain and lung metastases in BRCA1 carriers. 16687925 Human
brca1 metastatic breast cancer Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. 16739340 Human
brca1 metastatic breast cancer PATIENTS AND METHODS: To clarify these findings, BRCA1 expression in primary tumors was evaluated by immunohistochemistry in 50 patients with metastatic breast cancer. 16739340 Human
brca1 peritoneal cancers Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. 16835424 NA
brca1 peritoneal cancer OBJECTIVES: To estimate the incidence of ovarian, fallopian tube, and primary peritoneal cancer in women who carry a deleterious mutation in BRCA1 or BRCA2. 16835424 NA
brca1 fallopian tube cancer CONCLUSION: Oophorectomy is associated with reduced risk of ovarian and fallopian tube cancer in high-risk women, although there is a substantial residual risk for peritoneal cancer in BRCA1 and BRCA2 mutation carriers following prophylactic salpingo-ooph 16835424 Human
brca1 peritoneal cancer CONCLUSION: Oophorectomy is associated with reduced risk of ovarian and fallopian tube cancer in high-risk women, although there is a substantial residual risk for peritoneal cancer in BRCA1 and BRCA2 mutation carriers following prophylactic salpingo-ooph 16835424 Human
brca1 in situ carcinomas In the 22 BRCA1-mutated women, there were two in situ carcinomas and two atypical hyperplasias of the tubal epithelium. 14668548 Human
brca1 breast ovarian cancer syndrome The breast ovarian cancer syndrome is caused by mutations in the BRCA1 and BRCA2 genes and is associated with an 11-40% risk of developing ovarian cancer. 16050564 Human
brca1 ovarian malignancy Reducing death rates from ovarian malignancy has focussed on the unaffected females of families with a high chance of a mutant gene such as BRCA1 and BRCA2. 16390709 Human
brca1 ilc For BRCA1 (D17S855, THRA1, D17S579) losses could be detected in invasive ductal carcinoma (IDC; n = 108) in 32-38%, invasive lobular carcinoma (ILC; n = 19) in 21-42% depending on the marker applied, but not in benign breast tumours (n = 15). 8630282 Human
brca1 cervical carcinoma Immunoflourescence staining with an antibody to the carboxyl terminus of BRCA1 localized the protein to the nucleus of breast, ovarian, and cervical carcinoma-derived cell lines. 8910495 Human
brca1 lobular carcinoma in situ Lobular carcinoma in situ was less common in familial cancers (p = 0.013), but differences were not significant for BRCA1-mutations or BRCA2-mutation carriers, separately. 9167459 Human
brca1 hcc METHODS: The authors assessed the LOH of the 10 known tumor suppressor genes (VHL, APC, EXT1, WT1, Rb1, p53, BRCA1, nm23, DPC4, and DCC) with microsatellite markers in 29 consecutively resected HCC specimens. 9307185 Human
brca1 cowden syndrome The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. 9345101 Human
brca1 tumour antigens New developments include the use of: (i) intra-tumoural blood velocity as an end-point of colour Doppler imaging, (ii) serial measurements of serum tumour antigens to identify women for ultrasonography, and (iii) tests which detect regionally clustered ge 9484627 Human
brca1 solid tumors This interest has been heightened by recent discoveries that germ-line mutations such as BRCA1 and BRCA2 in hereditary breast cancer are responsible for an increasing percentage of common solid tumors. 9616736 Human
brca1 borderline ovarian tumors To gain insight into these issues, we determined the rates of 185delAG-BRCA1 and 6174delT-BRCA2 mutations in patients with borderline ovarian tumors. 9665148 Human
brca1 borderline ovarian tumors METHODS: Analysis of 185delAG-BRCA1 and 6174delT-BRCA2 germline mutations was performed by use of a heteroduplex formation assay in samples from 46 consecutive patients with borderline ovarian tumors and 59 consecutive patients with invasive epithelial ov 9665148 Human
brca1 borderline ovarian tumor In one high-risk family that included 185delAG-BRCA1 carriers, a single patient with stage IIIc borderline ovarian tumor did not carry the mutation. 9665148 Human
brca1 adenocarcinomas One common overlapping region of loss involved loci mapped to distal 17q24-proximal 17q25, which tentatively defines a potential chromosomal region distal to BRCA1 involved in the pathogenesis or progression of both types of adenocarcinomas. 9726814 Human
brca1 tumorigenesis These results raise the possibility that wild-type BRCA1 suppresses estrogen-dependent transcriptional pathways related to mammary epithelial cell proliferation and that loss of this ability contributes to tumorigenesis. 10334989 Human
brca1 hcc Formation of irradiation-induced foci positive for BRCA1, hRad50, hMre11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wild-type BRCA1. 10426999 Human
brca1 precancerous lesions OBJECTIVE: To determine the integrity of the BRCA1 gene in archival, paraffin-embedded tissues from precancerous lesions of the uterine cervix. 10442317 Human
brca1 precancerous lesions RESULTS: Mutation of the BRCA1 exon 11 gene was detected in > 76% of cases with precancerous lesions of the cervix. 10442317 Human
brca1 precancerous lesions CONCLUSION: The mutated BRCA1 gene was associated with 76% of 17 precancerous lesions of the cervix. 10442317 Human
brca1 cystadenomas RESULTS: The average percentage of BRCA1-positive cells was 5.6% in cystadenomas, 29.7% in borderline tumors, and 6.6% in OECs. 10684699 Human
brca1 papillary serous carcinoma of the peritoneum BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. 10728699 Human
brca1 metastasis We propose that the unique molecular pathogenesis of BRCA1-related PSCP may affect the ability of current methods to reliably prevent or detect this disease prior to metastasis. 10728699 Human
brca1 necrosis Breast cancers in non-BRCA1/2 families were of lower grade (P = 0.0018), showed fewer mitoses (P < 0.0001), less nuclear pleomorphism (P = 0.0014), less lymphocytic infiltrate (P < 0.0001), a lesser extent of the tumor with a continuous pushing margin (P 10741697 Human
brca1 dysgerminoma Of 66 patients from 36 BRCA1-positive families, 64 had ovarian carcinoma, 1 had an ovarian carcinoma in situ, and 1 had a dysgerminoma. 11112219 Human
brca1 primary peritoneal carcinoma Of 151 patients from 90 BRCA1-negative families, 135 had ovarian carcinoma, 10 had ovarian borderline tumors, 3 had ovarian sex cord/stromal tumors, and 3 had primary peritoneal carcinoma. 11112219 Human
brca1 ovarian borderline tumors Of 151 patients from 90 BRCA1-negative families, 135 had ovarian carcinoma, 10 had ovarian borderline tumors, 3 had ovarian sex cord/stromal tumors, and 3 had primary peritoneal carcinoma. 11112219 Human
brca1 stromal tumors Of 151 patients from 90 BRCA1-negative families, 135 had ovarian carcinoma, 10 had ovarian borderline tumors, 3 had ovarian sex cord/stromal tumors, and 3 had primary peritoneal carcinoma. 11112219 Human
brca1 leukemia The ratio of the full length, the delta(11q), the delta(9,10), and the delta(9,10,11q) BRCA1 isoforms showed different expression patterns in the examined breast and ovarian tumor cell lines as compared to the leukemia cell line. 11162473 Human
brca1 lymphoma The panel included cell lines with varying levels of karyotypic abnormalities, isogenic cell lines with normal and mutant p53, isogenic cell lines with or without DNA mismatch repair, BRCA1 and -2 mutant cell lines, and the lymphoma cell line DT40. 11178982 Human
brca1 lymphomas Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased nine-, five-, six- and threefold, respectively, among first-degree relatives of cases carrying BRCA1 mutations, compared with relatives of noncarriers, and risk of colore 11179017 Human
brca1 leukemias Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased nine-, five-, six- and threefold, respectively, among first-degree relatives of cases carrying BRCA1 mutations, compared with relatives of noncarriers, and risk of colore 11179017 Human
brca1 primary tumor METHODS: RNA from samples of primary tumor from seven carriers of the BRCA1 mutation, seven carriers of the BRCA2 mutation, and seven patients with sporadic cases of breast cancer was compared with a microarray of 6512 complementary DNA clones of 5361 gen 11207349 Human
brca1 atypical duct hyperplasia Retroviral transduction of splice variant Brca1-Delta11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia. 11889595 Mouse
brca1 carcinogenesis These results demonstrate a novel pathogenic mechanism whereby mutations in BRCA1, via a novel transcription factor complex containing BRCA1, c-Myc, and Nmi, impair inhibition of c-Myc-induced hTERT promoter activity, which allows sustained activation of 11916966 Human
brca1 osteosarcoma In this study, we monitored the activities of three members of the MAPK family (ERK1/2, JNK, p38) in MCF-7 breast cancer cells and U2OS osteosarcoma cells after their exposure to a recombinant adenovirus expressing wild type BRCA1 (Ad.BRCA1). 12082091 Human
brca1 b-cell chronic lymphocytic leukemia The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 acute myeloid leukemia (aml) The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 t-cell acute lymphoblastic leukemia (t-all) The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 lymphoma The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 follicular lymphoma (fl) The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 b-cell acute lymphoblastic leukemia (b-all) The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 diffuse large b-cell lymphoma The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 dlbcl The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 acute leukemia The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia 12217913 Human
brca1 malignant transformation Despite being implicated in many important cellular pathways, including DNA repair and regulation of transcription, the exact mechanism by which inactivation of BRCA1 might lead to malignant transformation of cells remains unknown. 12383682 Human
brca1 thymic lymphoma The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-delta11 thymocytes, eventually leading to thymic lymphoma formation. 12555066 Human
brca1 leukemia BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. 12576338 Human
brca1 lymphoma BRCA1 and BRCA2 germline mutations in lymphoma patients. 12691152 Human
brca1 lymphoma The observation of a germline BRCA1 mutation in an index case with a lymphoid neoplasm in the setting of a family history of breast cancer prompted us to explore the role of BRCA germline mutations as lymphoma susceptibility alleles. 12691152 Human
brca1 lymphoma A panel of 286 DNA samples from Jewish lymphoma patients was analyzed for the three most frequent BRCA1 and BRCA2 germline mutations in those of Ashkenazi Jewish heritage, and compared to a cohort of 5010 DNA samples from healthy controls. 12691152 Human
brca1 medullary carcinoma of the breast Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. 14614327 Human
brca1 adenocarcinomas Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. 14647419 Human
brca1 dysgerminoma Of 70 patients from 38 BRCA1-positive families, 69 had epithelial ovarian carcinoma and one had a dysgerminoma. 14668547 Human
brca1 atypical hyperplasias In the 22 BRCA1-mutated women, there were two in situ carcinomas and two atypical hyperplasias of the tubal epithelium. 14668548 Human
brca1 ptc The goals of the present study were to describe rates of completing a psychosocial telephone counseling (PTC) intervention that was offered to female BRCA1/2 mutation carriers and to identify sociodemographic and psychological factors associated with deci 15159322 Human
brca1 solid carcinoma BRCA1-related breast cancers are characterized by poor prognosis, a low rate of estrogen receptor positivity, and histological predominance of solid-tubular carcinoma. 15375703 Human
brca1 serous adenocarcinoma BRCA1-related ovarian cancers are associated with a high frequency of serous adenocarcinoma and a good outcome. 15375703 Human
brca1 adenocarcinomas Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERalpha expression 15750629 Mouse
brca1 adenoma Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands wit 15761464 Human
brca1 adenocarcinomas Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation. 16158938 Human
brca1 adenocarcinomas To address the relationship between the expression level of these genes and colorectal tumorigenesis, we studied BRCA1, BRCA2 and hMSH2 mRNA expression by real-time quantitative RT-PCR in 72 colorectal Lieberkühnien adenocarcinomas and matched normal muc 16158938 Human
brca1 cmm We performed a genome-wide scan of two Danish pedigrees with multiple cases of OMM (N = 10) and CMM (N = 3) and other malignancies (with no germline mutations in CDKN2A, CDK4, BRCA1, and BRCA2) to identify melanoma susceptibility genes. 16174859 Human
brca1 abdominal carcinomatosis Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". 16188301 Human
brca1 adenocarcinomas Targeted deletion of Brca1 in mammary epithelium resulted in carcinomas and adenocarcinomas of varying histology with long (>9 months) latency. 16204043 Human
brca1 osteosarcoma To further explore the role of BRCA1 and p53 in repair of photoproducts, we eliminated wild type p53 from U2OS osteosarcoma cells and found that cyclobutane pyrimidine dimer (CPD) repair was markedly impaired following UV damage whereas repair of 6-4 phot 16357511 Human
brca1 hnscc In the present study, 10 HNSCC cell lines were examined for expression of nine genes involved in the FANC-BRCA pathway by RT-PCR: FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, BRCA1 and BRCA2. 16466850 Human
brca1 mouse mammary tumors Consistently, Brca1-deficient mouse mammary tumors exhibit accelerated growth, pronounced vascularization, and overexpressed ANG1. 16843262 Mouse
brca1 lobular carcinoma RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyper 16908132 Human
brca1 ductal carcinoma RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyper 16908132 Human
brca1 atypical ductal hyperplasia RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyper 16908132 Human
brca1 atypical lobular hyperplasia RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyper 16908132 Human
brca1 childhood cancer Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. 16931905 Human
brca1 childhood cancers PATIENTS AND METHODS: We compared the prevalence of childhood cancers in 379 families with BRCA1 or BRCA2 mutations and 426 families without mutations. 16931905 Human
brca1 childhood cancer RESULTS: 20 cases of childhood cancer occurred in 379 families with BRCA1 or BRCA2 mutations and 35 cases of childhood cancer occurred in 426 families with negative mutation testing (p = 0.12). 16931905 Human
brca1 childhood cancers Nine childhood cancers occurred in 240 families with BRCA1 mutations, and 11 childhood cancers occurred in 141 families with BRCA2 mutations (p = 0.1). 16931905 Human
brca1 childhood cancer 13 of 18 families with childhood cancer and BRCA1 or BRCA2 mutations (72%) and 13 of 31 families with childhood cancer and negative mutation testing (42%) met the Birch criteria for Li-Fraumeni like syndrome (LFL). 16931905 Human
brca1 childhood cancer CONCLUSIONS: In this retrospective analysis, heterozygous BRCA1 and BRCA2 mutations were not a risk factor for childhood cancer in hereditary breast cancer families. 16931905 Human
brca1 ovarian metastasis Six clinically occult primary gynecologic malignancies (2 stage IIIC serous carcinomas of the ovary, 3 in situ serous carcinomas of the fallopian tube, and 1 stage IIB invasive serous carcinoma of the fallopian tube) and 1 occult ovarian metastasis from b 17001151 Human
brca1 serous carcinomas of the ovary Six clinically occult primary gynecologic malignancies (2 stage IIIC serous carcinomas of the ovary, 3 in situ serous carcinomas of the fallopian tube, and 1 stage IIB invasive serous carcinoma of the fallopian tube) and 1 occult ovarian metastasis from b 17001151 Human
brca1 medullary carcinomas Of note, medullary carcinomas are rare tumors, which are associated with germ-line mutations in the BRCA1 gene. 17035397 Human
brca1 therapy-related acute myeloid leukaemia Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. 17047656 Human
brca1 acute myeloid leukaemia (aml) We were interested in the regulation of BRCA1 expression in acute myeloid leukaemia (AML), in particular in therapy-related forms (t-AML). 17047656 Human
brca1 acute myeloid leukaemia Acute myeloid leukaemia samples showed heterogeneous BRCA1 mRNA levels, which were lower than those of normal bone marrows (P=0.0001). 17047656 Human
brca1 aml We found a high frequency of hypermethylation of the BRCA1 promoter region in AML (51/133 samples, 38%), in particular in patients with karyotypic aberrations (P=0.026), and in t-AML, as compared to de novo AML (76 vs 31%, P=0.0002). 17047656 Human
brca1 invasive cancer The test group included 21 cases of in situ and/or invasive cancer from carriers of either the IVS10-6T-->G, 2424V-->G or 1420L-->F ATM variants in the absence of BRCA1 or BRCA2 mutations. 17064299 Human
brca1 invasive cancers An additional four invasive cancers from carriers of a pathogenic BRCA1 mutation in the context of a familial ATM variant were also examined. 17064299 Human
brca1 sporadic breast cancer The analysis of the methylation level of the promoter of ERalpha, BRCA1, and E-cadherin, frequently connected with their activity, shows that it can be an important parameter in the diagnosis and therapeutic strategies in sporadic breast cancer. 17065058 Human
brca1 inclusion cysts Using mice with conditional expression of Brca1, we inactivated Brca1 in the murine OSE and demonstrate that this inactivation results in the development of preneoplastic changes, such as hyperplasia, epithelial invaginations, and inclusion cysts, which a 17070800 Mouse
brca1 intraepithelial carcinoma The tubal fimbria is a common site of origin for early (tubal intraepithelial carcinoma or TIC) serous carcinomas in women with familial BRCA1 or 2 mutations (BRCA+). 17117391 Human
brca1 serous carcinomas The tubal fimbria is a common site of origin for early (tubal intraepithelial carcinoma or TIC) serous carcinomas in women with familial BRCA1 or 2 mutations (BRCA+). 17117391 Human
brca1 tumorigenesis Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. 17138902 Mouse
brca1 breast cancer Women with mutations in the breast cancer susceptibility gene BRCA1 are predisposed to breast and ovarian cancers. 17138902 Human
brca1 breast and ovarian cancers Women with mutations in the breast cancer susceptibility gene BRCA1 are predisposed to breast and ovarian cancers. 17138902 Human
brca-1 gbm We report the case of a 46-year-old woman previously treated for ductal adenocarcinoma of the breast with BRCA-1 who subsequently was diagnosed with multicentric glioblastoma multiforme (GBM) in the right temporal and right occipital lobes. 16958968 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.